ADC Therapeutics IPO

ADC Therapeutics is a clinical-stage oncology biotechnology company leading the development and commercialization of next-generation antibody drug conjugates (ADCs) with highly potent and targeted pyrrolobenzodiazepine (PBD) dimer technology.

Total Funding to Date$200.02MM
Register for Details

For more details on financing and valuation for ADC Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

ADC Therapeutics Ticker Symbol


ADC Therapeutics Stock Price

$3.62 as of 12/2/22